Pain during cannulation · pain treatment during intravenous cannulation
1 finding from 1 review
Adverse events ‐ pain with topical application · pain treatment during intravenous cannulation
1 finding from 1 review
First‐attempt success rate · pain treatment during intravenous cannulation
Vapocoolant showed no clear difference in first attempt success compared with placebo/no treatment (moderate certainty).
1 finding from 1 review
Adverse events · pain treatment during intravenous cannulation
1 finding from 1 review
Nausea and vomiting ‐ subgroup analysis: thiopentone or halothane + N2O versus propofol or propofol + N2O · paediatric
Maintenance anaesthesia: inhalational may leads to higher nausea and vomiting ‐ subgroup analysis: thiopentone or halothane +… compared with intravenous (low certainty).
2 findings from 1 review
Intervention not reported
Hyponatraemia (serum sodium < 135 mmol/L) · children requiring intravenous fluid to maintain hydration
The intervention leads to lower hyponatraemia (serum sodium < 135 mmol/L) (high certainty).
1 finding from 1 review
Intervention not reported
Hypernatraemia · children requiring intravenous fluid to maintain hydration
The intervention showed no clear difference in hypernatraemia (low certainty).
1 finding from 1 review
Intervention not reported
Death · children requiring intravenous fluid to maintain hydration
1 finding from 1 review
Intervention not reported
Seizures · children requiring intravenous fluid to maintain hydration
The intervention showed no clear difference in seizures (low certainty).
1 finding from 1 review
Intervention not reported
Cerebral oedema · children requiring intravenous fluid to maintain hydration
It is very uncertain whether the intervention changes cerebral oedema (very low certainty).
1 finding from 1 review
Intervention not reported
Overhydration · children requiring intravenous fluid to maintain hydration
The intervention showed no clear difference in overhydration (low certainty).
1 finding from 1 review
All‐cause mortality · people with cancer who have febrile neutropenia
Oral showed no clear difference in mortality compared with intravenous antibiotic therapy (moderate certainty).
1 finding from 1 review
Treatment failure · people with cancer who have febrile neutropenia
Oral showed no clear difference in treatment failure compared with intravenous antibiotic therapy (moderate certainty).
1 finding from 1 review
Treatment failure ‐ per protocol analysis · people with cancer who have febrile neutropenia
Oral showed no clear difference in treatment failure ‐ per protocol analysis compared with intravenous antibiotic therapy (moderate certainty).
1 finding from 1 review
Adverse events requiring discontinuation of antibiotics · people with cancer who have febrile neutropenia
Oral showed no clear difference in adverse events requiring discontinuation of antibiotics compared with intravenous antibiotic therapy (low certainty).
1 finding from 1 review
Treatment failure not dt modification in update · people with cancer who have febrile neutropenia
Oral showed no clear difference in treatment failure not dt modification in update compared with intravenous antibiotic therapy (moderate certainty).
1 finding from 1 review
Clinical relapse · patients with Crohn's disease (active disease population with clinical response at baseline)
It is very uncertain whether subcutaneous CT‐P13 and purine analogues changes clinical relapse (at 22 weeks, CDAI > 150) compared with intravenous CT‐P13 and purine analogues (very low certainty).
1 finding from 1 review
Loss of clinical response (at 22 weeks, less than 100 points in CDAI change) · patients with Crohn's disease (active disease population with clinical response at baseline)
It is very uncertain whether subcutaneous CT‐P13 and purine analogues changes loss of clinical response (at 22 weeks, less than 100 points in CDAI… compared with intravenous CT‐P13 and purine analogues (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · patients with Crohn's disease (active disease population with clinical response at baseline)
It is very uncertain whether subcutaneous CT‐P13 and purine analogues changes withdrawal due to adverse events (at 30 weeks) compared with intravenous CT‐P13 and purine analogues (very low certainty).
1 finding from 1 review
Serious adverse events · patients with Crohn's disease (active disease population with clinical response at baseline)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found